ZSCAN5A: A Potential Drug Target and Biomarker (G79149)

Target Name: ZSCAN5A

NCBI ID: G79149

ZSCAN5A

ZSCAN5A: A Potential Drug Target and Biomarker

Zinc finger and SCAN domain containing 5 (ZSCAN5A) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer. The ZSCAN5A gene has been shown to be involved in a wide range of physiological processes, including cell signaling, DNA replication, and response to stress.

The ZSCAN5A protein is a 21-kDa protein that is expressed in various tissues and cells, including brain, muscle, heart, and cancer cells. It is composed of a zinc finger domain and a SCAN domain, which are both conserved domains that are found in various proteins that play important roles in cellular signaling. The zinc finger domain is responsible for the formation of a zinc ion bridge, which can activate a protein kinase and modulate cellular signaling pathways. The SCAN domain is responsible for the formation of ascanide bonds, which are involved in DNA replication and repair.

Several studies have shown that the ZSCAN5A protein is involved in a wide range of cellular processes that are important for human health and disease. For example, ZSCAN5A has been shown to be involved in cell signaling pathways that are important for brain development and function, including the regulation of neurotransmitter release and cell survival. It has also been shown to be involved in the regulation of cellular responses to stress, including the regulation of cell cycle progression and the expression of stress-responsive genes.

In addition to its involvement in cellular signaling pathways, ZSCAN5A has also been shown to be involved in the regulation of DNA replication and repair. Several studies have shown that ZSCAN5A is involved in the regulation of DNA replication, including the regulation of the number of replication starting point and the efficiency of DNA replication. It has also been shown to be involved in the regulation of DNA repair, including the regulation of the repair process and the efficiency of DNA repair.

Given the involvement of ZSCAN5A in a wide range of cellular processes that are important for human health and disease, it is a potential drug target for various diseases. For example, ZSCAN5A has been shown to be involved in the regulation of neurotransmitter release, which is important for the function of the brain and body. Therefore, ZSCAN5A may be a potential drug target for disorders of the brain, such as Alzheimer's disease, Parkinson's disease, and depression.

In addition to its potential as a drug target, ZSCAN5A has also been shown to be a potential biomarker for various diseases. For example, ZSCAN5A has been shown to be involved in the regulation of cellular responses to stress, which is a potential biomarker for a variety of diseases, including cancer. Therefore, ZSCAN5A may be a potential biomarker for cancer, including breast, ovarian, and prostate cancers.

Overall, the ZSCAN5A protein is a promising drug target and biomarker for various diseases. Further research is needed to fully understand its role in cellular signaling pathways and its potential as a drug and biomarker.

Protein Name: Zinc Finger And SCAN Domain Containing 5A

Functions: May be involved in transcriptional regulation

The "ZSCAN5A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZSCAN5A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets